February 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountpadcev.com
Global Rank
#547,084
286,243Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
68.87%
Pages per Visit
1.56
Avg Visit Duration
00:00:42
- Company
- - -
- Industry
- - -
Top 10 padcev.com Competitors
The Top 10 Sites Like padcev.com in February 2026 are ranked by their affinity to padcev.com in terms of keyword traffic, audience targeting, and market overlap
Learn about BAVENCIO® (avelumab) as the first and only immunotherapy approved for the first-line maintenance treatment of metastatic urothelial carcinoma. Learn more
- Company
- - -
- Industry
- - -
Global Rank
#4,524,056
975,428Bounce Rate
43.54%
Pages per Visit
1.77
Avg Visit Duration
00:00:35
Similarity Score
100%Evaluate ORSERDU®, a treatment option for ESR1-mutated, ER+/HER2-advanced or metastatic breast cancer following disease progression on endocrine therapy.
- Company
- - -
- Industry
- - -
Bounce Rate
76.9%
Pages per Visit
1.53
Avg Visit Duration
00:00:50
Similarity Score
98%health care professionals may find information about fda-approved indications for keytruda® (pembrolizumab) along with keynote clinical trials and treatment guidelines.
- Company
- - -
- Industry
- - -
Global Rank
#835,877
23,457Bounce Rate
59.02%
Pages per Visit
1.35
Avg Visit Duration
00:00:33
Similarity Score
96%Click to learn more information.
- Company
- - -
- Industry
- - -
Global Rank
#1,245,116
390,757Bounce Rate
68.77%
Pages per Visit
1.32
Avg Visit Duration
00:00:20
Similarity Score
94%Discover EPKINLY® (epcoritamab-bysp). See full Prescribing Information and Boxed Warnings.
- Company
- - -
- Industry
- - -
Bounce Rate
79.95%
Pages per Visit
1.16
Avg Visit Duration
00:00:35
Similarity Score
93%CABOMETYX® (cabozantinib) is a multi-indication cancer treatment FDA-approved for 1L & 2L aRCC, 2L HCC and 2L DTC. See Important Safety Information.
- Company
- - -
- Industry
- - -
Bounce Rate
71.08%
Pages per Visit
1.43
Avg Visit Duration
00:01:21
Similarity Score
92%Please see Important Safety Information and full Prescribing Information.
- Company
- - -
- Industry
- - -
Global Rank
#1,094,678
247,340Bounce Rate
70.25%
Pages per Visit
1.25
Avg Visit Duration
00:02:02
Similarity Score
91%See risks & benefits. Learn about BRAFTOVI® (encorafenib) + cetuximab, an oral Rx treatment taken once a day for adults with previously treated BRAF+ V600E metastatic CRC.
- Company
- - -
- Industry
- - -
Bounce Rate
74.94%
Pages per Visit
1.67
Avg Visit Duration
00:03:42
Similarity Score
89%Learn more about a targeted therapy like XOSPATA.
- Company
- - -
- Industry
- - -
Bounce Rate
88.85%
Pages per Visit
1.23
Avg Visit Duration
00:00:21
Similarity Score
88%Novocure (NASDAQ: NVCR) is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields.
- Company
- Novocure
Global Rank
#626,981
181,063Bounce Rate
41.49%
Pages per Visit
2.63
Avg Visit Duration
00:01:00
Similarity Score
87%padcev.com's top 5 competitors in February 2026 are: bavencio.com, orserdu.com, keytrudahcp.com, imfinzi.com, and more.
According to Similarweb data of monthly visits, padcev.com’s top competitor in February 2026 is bavencio.com. padcev.com 2nd most similar site is orserdu.com, and closing off the top 3 is keytrudahcp.com.
imfinzi.com ranks as the 4th most similar website to padcev.com and epkinly.com ranks fifth in February 2026.
The other five competitors in the top 10 list are cabometyxhcp.com, ninlaro.com, braftovi.com, xospatahcp.com, and novocure.com.